{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:01Z","timestamp":1792099561060,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2019,9,13]]},"DOI":"10.1007\/s10384-019-00685-4","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T13:02:26Z","timestamp":1566219746000},"page":"365-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Current practice in the management of branch retinal vein occlusion in Japan: Survey results of retina specialists in Japan"],"prefix":"10.1007","volume":"63","author":[{"given":"Yuichiro","family":"Ogura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Kadonosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"685_CR1","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/j.1538-7836.2010.03909.x","volume":"8","author":"M Rehak","year":"2010","unstructured":"Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost. 2010;8:1886\u201394.","journal-title":"J Thromb Haemost"},{"key":"685_CR2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313\u20139.","journal-title":"Ophthalmology"},{"key":"685_CR3","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1167\/iovs.09-4453","volume":"51","author":"M Yasuda","year":"2010","unstructured":"Yasuda M, Kiyohara Y, Arakawa S, Hata Y, Yonemoto K, Doi Y, et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study. Investig Ophthalmol Vis Sci. 2010;51:3205\u20139.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"685_CR4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0161-6420(93)31633-7","volume":"100","author":"J Zhao","year":"1993","unstructured":"Zhao J, Sastry SM, Sperduto RD, Chew EY, Remaley NA. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology. 1993;100:423\u20138.","journal-title":"Ophthalmology."},{"key":"685_CR5","doi-asserted-by":"publisher","first-page":"CD008732","DOI":"10.1002\/14651858.cd008732.pub2","volume":"2015","author":"FC Lam","year":"2015","unstructured":"Lam FC, Chia SN, Lee RM. Macular grid laser photocoagulation for branch retinal vein occlusion. Cochrane Database Syst Rev. 2015;2015:CD008732. https:\/\/doi.org\/10.1002\/14651858.cd008732.pub2 .","journal-title":"Cochrane Database Syst Rev"},{"key":"685_CR6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12325-010-0089-3","volume":"28","author":"AA Aref","year":"2011","unstructured":"Aref AA, Scott IU. Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update. Adv Ther. 2011;28:28\u201339.","journal-title":"Adv Ther"},{"issue":"1094\u2013101","key":"685_CR7","first-page":"e5","volume":"117","author":"SL Rogers","year":"2010","unstructured":"Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(1094\u2013101):e5.","journal-title":"Ophthalmology"},{"key":"685_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0002-9394(79)90193-4","volume":"87","author":"PC Wetzig","year":"1979","unstructured":"Wetzig PC. The treatment of acute branch vein occlusion by photocoagulation. Am J Ophthalmol. 1979;87:65\u201373.","journal-title":"Am J Ophthalmol"},{"key":"685_CR9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2174\/157339912800840523","volume":"8","author":"JK Luttrull","year":"2012","unstructured":"Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012;8:274\u201384.","journal-title":"Curr Diabetes Rev"},{"key":"685_CR10","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480\u20137. https:\/\/doi.org\/10.1056\/NEJM199412013312203 .","journal-title":"N Engl J Med"},{"key":"685_CR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00417-008-0980-7","volume":"247","author":"E St\u00e9fansson","year":"2009","unstructured":"St\u00e9fansson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 2009;247:147\u201363.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1134\u201346","key":"685_CR12","first-page":"e3","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(1134\u201346):e3.","journal-title":"Ophthalmology"},{"key":"685_CR13","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122:538\u201344.","journal-title":"Ophthalmology"},{"issue":"1102\u201312","key":"685_CR14","first-page":"e1","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(1102\u201312):e1.","journal-title":"Ophthalmology"},{"key":"685_CR15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2016.02.030","volume":"123","author":"R Tadayoni","year":"2016","unstructured":"Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S, et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology. 2016;123:1332\u201344.","journal-title":"Ophthalmology"},{"key":"685_CR16","doi-asserted-by":"publisher","first-page":"009510","DOI":"10.1002\/14651858.cd009510.pub2","volume":"2013","author":"D Mitry","year":"2013","unstructured":"Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev. 2013;2013:009510. https:\/\/doi.org\/10.1002\/14651858.cd009510.pub2 .","journal-title":"Cochrane Database Syst Rev"},{"key":"685_CR17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11096-014-9918-9","volume":"36","author":"M Demir","year":"2014","unstructured":"Demir M, Oba E, Guven D, Acar Z, Cinar S. Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion. Int J Clin Pharm. 2014;36:438\u201342.","journal-title":"Int J Clin Pharm"},{"key":"685_CR18","doi-asserted-by":"crossref","first-page":"251257","DOI":"10.1155\/2014\/251257","volume":"2014","author":"K Inagaki","year":"2014","unstructured":"Inagaki K, Ohkoshi K, Ohde S, Deshpande GA, Ebihara N, Murakami A. Subthreshold micropulse photocoagulation for persistent macular edema secondary to branch retinal vein occlusion including best-corrected visual acuity greater than 20\/40. J Ophthalmol. 2014;2014:251257.","journal-title":"J Ophthalmol"},{"key":"685_CR19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/15569527.2015.1074586","volume":"35","author":"M Kola","year":"2016","unstructured":"Kola M, Hacioglu D, Turk A, Erdol H. The effectiveness and reliability of posterior sub-Tenon triamcinolone acetonide injection in branch retinal vein occlusion-related macular edema. Cutan Ocul Toxicol. 2016;35:185\u20139.","journal-title":"Cutan Ocul Toxicol"},{"key":"685_CR20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/OPTH.S123419","volume":"11","author":"A Nishida","year":"2017","unstructured":"Nishida A, Kojima H, Kameda T, Mandai M, Kurimoto Y. Five-year outcomes of pars plana vitrectomy for macular edema associated with branch retinal vein occlusion. Clin Ophthalmol. 2017;11:369\u201375.","journal-title":"Clin Ophthalmol"},{"key":"685_CR21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10384-018-0586-5","volume":"62","author":"H Iijima","year":"2018","unstructured":"Iijima H. Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion. Jpn J Ophthalmol. 2018;62:265\u201373.","journal-title":"Jpn J Ophthalmol"},{"key":"685_CR22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ajo.2007.09.019","volume":"145","author":"M Ota","year":"2008","unstructured":"Ota M, Tsujikawa A, Murakami T, Yamaike N, Sakamoto A, Kotera Y, et al. Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2008;145:273\u201380.","journal-title":"Am J Ophthalmol"},{"key":"685_CR23","doi-asserted-by":"crossref","first-page":"e0144894","DOI":"10.1371\/journal.pone.0144894","volume":"10","author":"Y Muraoka","year":"2015","unstructured":"Muraoka Y, Tsujikawa A, Takahashi A, Iida Y, Murakami T, Ooto S, et al. Foveal damage due to subfoveal hemorrhage associated with branch retinal vein occlusion. PLoS One. 2015;10:e0144894.","journal-title":"PLoS One"},{"key":"685_CR24","doi-asserted-by":"crossref","first-page":"e0153817","DOI":"10.1371\/journal.pone.0153817","volume":"11","author":"K Manabe","year":"2016","unstructured":"Manabe K, Tsujikawa A, Osaka R, Nakano Y, Fujita T, Shiragami C, et al. Metamorphopsia associated with branch retinal vein occlusion. PLoS One. 2016;11:e0153817.","journal-title":"PLoS One"},{"issue":"8","key":"685_CR25","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/IAE.0000000000001740","volume":"38","author":"Y Sugiura","year":"2018","unstructured":"Sugiura Y, Okamoto F, Morikawa S, Okamoto Y, Hiraoka T, Oshika T. Time course of changes in metamorphopsia following intravitreal ranibizumab injection for branch retinal vein occlusion. Retina. 2018;38(8):1581\u20137.","journal-title":"Retina"},{"key":"685_CR26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/archopht.1992.01080220089028","volume":"110","author":"D Finkelstein","year":"1992","unstructured":"Finkelstein D. Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol. 1992;110:1427\u201334.","journal-title":"Arch Ophthalmol."},{"key":"685_CR27","first-page":"39","volume":"7","author":"S Sakimoto","year":"2013","unstructured":"Sakimoto S, Kamei M, Suzuki M, Yano S, Matsumura N, Sakaguchi H, et al. Relationship between grades of macular perfusion and foveal thickness in branch retinal vein occlusion. Clin Ophthalmol. 2013;7:39\u201345.","journal-title":"Clin Ophthalmol"},{"key":"685_CR28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10384-017-0546-5","volume":"62","author":"H Iijima","year":"2018","unstructured":"Iijima H. Reduced light sensitivity due to impaired retinal perfusion in branch retinal vein occlusion. Jpn J Ophthalmol. 2018;62:151\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"685_CR29","doi-asserted-by":"crossref","first-page":"29445","DOI":"10.1038\/srep29445","volume":"6","author":"T Tomiyasu","year":"2016","unstructured":"Tomiyasu T, Hirano Y, Yoshida M, Suzuki N, Nishiyama T, Uemura A, et al. Microaneurysms cause refractory macular edema in branch retinal vein occlusion. Sci Rep. 2016;6:29445.","journal-title":"Sci Rep."},{"key":"685_CR30","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","volume":"118","author":"DM Brown","year":"2011","unstructured":"Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118:1594\u2013602.","journal-title":"Ophthalmology"},{"key":"685_CR31","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","volume":"119","author":"MA Singer","year":"2012","unstructured":"Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175\u201383.","journal-title":"Ophthalmology"},{"key":"685_CR32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT Study. Ophthalmology. 2016;123:330\u20136.","journal-title":"Ophthalmology"},{"key":"685_CR33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","volume":"98","author":"Group BVOS","year":"1984","unstructured":"Group BVOS. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984;98:271\u201382.","journal-title":"Am J Ophthalmol"},{"key":"685_CR34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archopht.1986.01050130044017","volume":"104","author":"Group BVOS","year":"1986","unstructured":"Group BVOS. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol. 1986;104:34\u201341.","journal-title":"Arch Ophthalmol"},{"key":"685_CR35","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","volume":"124","author":"R Tadayoni","year":"2017","unstructured":"Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER Study. Ophthalmology. 2017;124:1778\u201387.","journal-title":"Ophthalmology"},{"key":"685_CR36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/08820538.2013.833271","volume":"29","author":"IP Chatziralli","year":"2014","unstructured":"Chatziralli IP, Jaulim A, Peponis VG, Mitropoulos PG, Moschos MM. Branch retinal vein occlusion: treatment modalities: an update of the literature. Semin Ophthalmol. 2014;29:85\u2013107.","journal-title":"Semin Ophthalmol"},{"key":"685_CR37","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","volume":"127","author":"IU Scott","year":"2009","unstructured":"Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115\u201328.","journal-title":"Arch Ophthalmol"},{"key":"685_CR38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/2013.jamaophthalmol.228","volume":"131","author":"H Noma","year":"2013","unstructured":"Noma H, Mimura T, Eguchi S. Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol. 2013;131:160\u20135.","journal-title":"JAMA Ophthalmol"},{"key":"685_CR39","first-page":"155","volume":"30","author":"Y Yanagi","year":"2013","unstructured":"Yanagi Y. Update on treatment of retinal vein occlusion. J Eye. 2013;30:155\u201363 [in Japanese].","journal-title":"J Eye"},{"key":"685_CR40","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/eye.2016.96","volume":"30","author":"J Moon","year":"2016","unstructured":"Moon J, Kim M, Sagong M. Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. Eye (Lond). 2016;30:1084\u201390.","journal-title":"Eye (Lond)"},{"key":"685_CR41","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s10384-018-0628-z","volume":"62","author":"Y Yamada","year":"2018","unstructured":"Yamada Y, Takamura Y, Matsumura T, Morioka M, Gozawa M, Inatani M. Posterior subtenon infusion of triamcinolone acetonide as adjunctive treatment to panretinal photocoagulation using pattern scan laser for diabetic retinopathy. Jpn J Ophthalmol. 2018;62:686\u201392.","journal-title":"Jpn J Ophthalmol"},{"key":"685_CR42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s10384-012-0121-z","volume":"56","author":"S Harino","year":"2012","unstructured":"Harino S, Bessho K, Kida T. Prospective multicenter study of visual outcomes following three different treatments for macular edema associated with branch retinal vein occlusion: a study by the Japanese BRVO study group. Jpn J Ophthalmol. 2012;56:250\u201361.","journal-title":"Jpn J Ophthalmol"},{"key":"685_CR43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.47102\/annals-acadmedsg.V41N7p294","volume":"41","author":"T Sato","year":"2012","unstructured":"Sato T, Sawada K, Iwahashi-Shima C, Bando H, Ikeda T, Emi K. 25-gauge vitrectomy versus intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion: 1\u00a0year follow-up. Ann Acad Med Singap. 2012;41:294\u20139.","journal-title":"Ann Acad Med Singap"},{"key":"685_CR44","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1167\/iovs.12-10164","volume":"53","author":"M Kakinoki","year":"2012","unstructured":"Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Investig Ophthalmol Vis Sci. 2012;53:5877\u201380.","journal-title":"Investig Ophthalmol Vis Sci"}],"updated-by":[{"DOI":"10.1007\/s10384-020-00739-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000}}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-019-00685-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-019-00685-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-019-00685-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:07:06Z","timestamp":1695107226000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-019-00685-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9,13]]}},"alternative-id":["685"],"URL":"https:\/\/doi.org\/10.1007\/s10384-019-00685-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10384-020-00739-y","asserted-by":"object"}]},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"15 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication, under section, BRVO treatment practice pattern, the sentence in p. 369 was published as.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Ogura, Consultant fee (Bayer, Alcon, Janssen Pharma, Kowa, Novartis, Sanwa Kagaku, Senju, Wakamoto), Speaker Fee (Santen, Topcon, Wakamoto), Grant (Novartis, Santen); M. Kondo, Grant (Novartis); K. Kadonosono, None; M. Shimura, None; M. Kamei, Speaker fee (Alcon, AMO, Bayer, Bausch & Lomb, Ellex, HOYA, Johnson & Johnson, Kowa, Nidek, Novartis, Otsuka, Pfizer, Santen, Senju), Consultant fee (Astellas, HOYA, Nidek, Senju), Grant (Alcon, AMO, Bayer, HOYA, Kowa, Nidek, Novartis, Otsuka, Pfizer, Santen, Senju); A. Tsujikawa, Lecture fee (Pfizer, Bayer, Santen, Novartis, Senju, Alcon, Nidek, AMO, Kowa, Chugai, Sanwa Kagaku, Astellas Pharma, Johnson & Johnson, Alcon Pfarma, Otsuka, Ezai), Grant (Pfizer, Bayer, Japan Society for the Promotion of Science, Santen, Novartis, Senju, Alcon, AMO, Hoya, Kowa, Alcon Pharma, Otsuka).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}